FTC Requires Divestitures in Connection With Impax Laboratories Inc.’s Proposed Acquisition of CorePharma, LLC

Pharmaceutical companies Impax Laboratories Inc. and CorePharma, LLC have agreed to divest all of CorePharma’s rights and assets to generic pilocarpine tablets and generic ursodiol tablets, in order to settle Federal Trade Commission charges that Impax’s proposed $700 million acquisition of CorePharma would likely be anticompetitive. Perrigo Company plc, a global drug company headquartered in Ireland that markets generic drugs in the United States, will acquire the divested assets. [3/11/15]